Boehringer Ingelheim has established a partnership with two divisions of Omnicare Specialty Care Group, which specializes in providing comprehensive pharmaceutical services designed to support their patients suffering from idiopathic pulmonary fibrosis (IPF) and prescribes newly-approved OFEV capsules (nintedanib) for IPF treatment. The agreement aims to improve healthcare and reduce costs.
RxCrossroads and Advanced Care Scripts are the two divisions of Omincare Specialty Care Group that were chosen to assist patients undergoing OFEV, which is an oral therapy recently approved by the U.S. Food and Drug Administration. It is the only kinase inhibitor approved to treat the rare and fatal lung disease that strikes about 132,000 people in the United States alone.
“Omnicare SCG is pleased to support this effective treatment option,” said the chief executive officer of Omnicare, Nitin Sahney. “Through our partnership with Boehringer Ingelheim and support of OFEV, we are proud to have the opportunity to support the thousands of patients living with this unfortunate disease and provide solutions for their current unmet need.”
RxCrossroads will be responsible for processing reimbursements and providing support services to not only patients, but also caregivers and healthcare providers working with OFEV, according to the partnership agreement. With experience in management payer coverage, coding, and reimbursement assistance services, the company has been committed to creating, implementing, and carrying out customized clinical programs to facilitate their patients’ lives.
Advanced Care Scripts, on the other hand, was selected due to its position in the limited distribution specialty pharmacy network, and is going to be in charge of clinical support and product dispensing all over the country. The company specializes in the management and provision of specialty medication for several disease categories, and has been particularly dedicated to the healthcare of patients with severe respiratory diseases.